BRAF V600E Prevalence in Lung Adenocarcinoma
BRAF V600E mutation occurs in 1-2% of all lung adenocarcinomas 1. This prevalence applies broadly to lung adenocarcinoma regardless of differentiation status, as the available evidence does not stratify mutation rates by tumor grade.
Key Epidemiological Data
The most authoritative source, the 2024 NCCN Guidelines, consistently states that BRAF V600E represents 1-2% of lung adenocarcinomas and is the most common BRAF mutation across all tumor types 1. The 2023 ESMO Guidelines corroborate this range, noting 1-5% prevalence in some populations 2.
Population-Specific Variations
Research studies reveal some geographic and demographic variability:
- Chinese populations: Studies show 1.5% overall BRAF mutation prevalence 3, with V600E specifically at 4.2% in one cohort 4
- Western populations: The Lung Cancer Mutation Consortium found 2.2% BRAF mutations overall, with 81% being V600E 5
- Montenegrin cohort: Recent data showed 1.5% V600E prevalence 6
Among BRAF-mutated cases specifically, V600E represents approximately 40-81% of all BRAF mutations 5, 7, with the remainder being non-V600E variants (N581I, G593S, V600K, V600D).
Clinical Context for Poorly Differentiated Tumors
No evidence specifically addresses whether poorly differentiated acinar adenocarcinomas have different BRAF V600E mutation rates than well-differentiated tumors. However, one Chinese study found that in patients under 60 years, BRAF mutations were associated with poor differentiation (70% vs 35.1%, p=0.014) 3, suggesting possible enrichment in poorly differentiated tumors in younger patients.
Important Clinical Associations
BRAF V600E mutations show distinct patterns:
- More common in current/former smokers (82% vs 36% in EGFR-mutated cases) 5
- Slight female predominance (6.3% in women vs lower in men, though not statistically significant) 4
- Higher co-mutation rate: 16% of BRAF-mutated cases harbor additional driver mutations, compared to 5% in other genomic subtypes 5
Testing Implications
Given the 1-2% prevalence and availability of FDA-approved targeted therapies (dabrafenib-trametinib, encorafenib-binimetinib), comprehensive molecular profiling including BRAF testing is essential for all lung adenocarcinomas 1. VE1 immunohistochemistry can serve as an initial screening tool, with strong homogeneous (3+) cytoplasmic staining predicting V600E mutation with high accuracy 6, though molecular confirmation remains necessary for weak or heterogeneous staining patterns.